H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 27.3 HKD -2.15% Market Closed
Market Cap: 23.8B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

HUTCHMED (China) Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

HUTCHMED (China) Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
H
HUTCHMED (China) Ltd
HKEX:13
Change in Working Capital
-$10.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Change in Working Capital
-HK$594.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
SSY Group Ltd
HKEX:2005
Change in Working Capital
HK$785.1m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
3%
U
United Laboratories International Holdings Ltd
HKEX:3933
Change in Working Capital
-ÂĄ1.4B
CAGR 3-Years
-73%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Sino Biopharmaceutical Ltd
HKEX:1177
Change in Working Capital
-ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Change in Working Capital
HK$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
23.8B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Intrinsic Value
21.49 HKD
Overvaluation 21%
Intrinsic Value
Price
H

See Also

What is HUTCHMED (China) Ltd's Change in Working Capital?
Change in Working Capital
-10.7m USD

Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Change in Working Capital amounts to -10.7m USD.

Back to Top